Skip directly to content

Safety Information

DETROL® LA(tolterodine L-tartrate)

Indications and Clinical Use:

Detrol LA is indicated for the symptomatic management of patients with an overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence, or any combination of these symptoms.

Safety and effectiveness in pediatric populations have not been established.


  • Urinary retention
  • Gastric retention
  • Uncontrolled narrow angle glaucoma

Relevant warnings and precautions:

  • Patients at risk of urinary retention and gastric retention
  • Patients with congenital or acquired QT prolongation
  • Monitoring of the QT/QTc interval and/or serum electrolytes in high risk patients
  • Patients with myasthenia gravis
  • Patients with controlled narrow angle glaucoma
  • Patients with impaired hepatic function
  • Patients with impaired renal function
  • Contraception in women of childbearing potential
  • Should be avoided during breastfeeding

For more information:

Please consult the product monograph by clicking here for important information relating to adverse reactions, drug interactions, and dosing information (including dose adjustments in renal impairment).

DETROL® LA Pfizer Enterprises SARL, owner/Pfizer Canada Inc., Licensee